Complement activation in experimental and human temporal lobe epilepsy

Neurobiology of Disease

Volumn 26, Issue 3, 2007, Pages 497-511

  Aronica, E ^a   Boer, K ^a   van Vliet, E A ^b,c   Redeker, S ^a   Baayen, J C ^d   Spliet, W G M ^e   van Rijen, P C ^f   Troost, D ^a   Lopes da Silva, F H ^b   Wadman, W J ^b   Gorter, J A ^b,c  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c STICHTING EPILEPSIE INSTELLINGEN NEDERLAND SEIN   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Astrocytes; Epileptogenesis; Hippocampus; Human; Immunocytochemistry; Microarray; Microglia; Neurons; PCR; Rat

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3D;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; GENE EXPRESSION; HIPPOCAMPUS; MACROGLIA; MALE; MICROGLIA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; TEMPORAL LOBE EPILEPSY; UPREGULATION;

ADOLESCENT; ADULT; AGED; ANIMALS; ASTROCYTES; COMPLEMENT C1Q; COMPLEMENT C3C; COMPLEMENT C3D; COMPLEMENT C5B; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; ENCEPHALITIS; EPILEPSY, TEMPORAL LOBE; FEMALE; GLIOSIS; HIPPOCAMPUS; HUMANS; MALE; MICROGLIA; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STATUS EPILEPTICUS; UP-REGULATION;

EID: 34248563861     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.01.015     Document Type: Article

References (72)

1. Alexander J.J., Bao L., Jacob A., Kraus D.M., Holers V.M., and Quigg R.J. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim. Biophys. Acta 1639 (2003) 169-176
2. Armstrong D.D. The neuropathology of temporal lobe epilepsy. J. Neuropathol. Exp. Neurol. 52 (1993) 433-443
3. Aronica E., van Vliet E.A., Mayboroda O.A., Troost D., da Silva F.H., and Gorter J.A. Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. Eur. J. Neurosci. 12 (2000) 2333-2344
4. Aronica E., Leenstra S., Jansen G.H., van Veelen C.W., Yankaya B., and Troost D. Expression of brain-derived neurotrophic factor and tyrosine kinase B receptor proteins in glioneuronal tumors from patients with intractable epilepsy: colocalization with N-methyl-d-aspartic acid receptor. Acta Neuropathol. (Berl). 101 (2001) 383-392
5. Aronica E., van Vliet E.A., Hendriksen E., Troost D., Lopes da Silva F.H., and Gorter J.A. Cystatin C, a cysteine protease inhibitor, is persistently up-regulated in neurons and glia in a rat model for mesial temporal lobe epilepsy. Eur. J. Neurosci. 14 (2001) 1485-1491
6. Aronica E., Gorter J.A., Jansen G.H., van Veelen C.W., van Rijen P.C., Ramkema M., and Troost D. Expression and cell distribution of group I and group II metabotropic glutamate receptor subtypes in taylor-type focal cortical dysplasia. Epilepsia 44 (2003) 785-795
7. Aronica E., Gorter J.A., Redeker S., Ramkema M., Spliet W.G., van Rijen P.C., Leenstra S., and Troost D. Distribution, characterization and clinical significance of microglia in glioneuronal tumours from patients with chronic intractable epilepsy. Neuropathol. Appl. Neurobiol. 31 (2005) 280-291
8. Barnum S.R., and Jones J.L. Differential regulation of C3 gene expression in human astroglioma cells by interferon-gamma and interleukin-1 beta. Neurosci. Lett. 197 (1995) 121-124
9. Basaran N., Hincal F., Kansu E., and Ciger A. Humoral and cellular immune parameters in untreated and phenytoin- or carbamazepine-treated epileptic patients. Int. J. Immunopharmacol. 16 (1994) 1071-1077
10. Becker A.J., Klein H., Baden T., Aigner L., Normann S., Elger C.E., Schramm J., Wiestler O.D., and Blumcke I. Mutational and expression analysis of the reelin pathway components CDK5 and doublecortin in gangliogliomas. Acta Neuropathol. 104 (2002) 403-408
11. Bellander B.M., Singhrao S.K., Ohlsson M., Mattsson P., and Svensson M. Complement activation in the human brain after traumatic head injury. J. Neurotrauma 18 (2001) 1295-1311
12. Block M.L., and Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76 (2005) 77-98
13. Blumcke I., Thom M., and Wiestler O.D. Ammon's horn sclerosis: a maldevelopmental disorder associated with temporal lobe epilepsy. Brain Pathol. 12 (2002) 199-211
14. Boer K., Spliet W.G., van Rijen P.C., Redeker S., Troost D., and Aronica E. Evidence of activated microglia in focal cortical dysplasia. J. Neuroimmunol. 173 (2006) 188-195
15. Bonifati D.M., and Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol. (2006) May 12; [Epub ahead of print]
16. Brink B.P., Veerhuis R., Breij E.C., van der Valk P., Dijkstra C.D., and Bo L. The pathology of multiple sclerosis is location-dependent: no significant complement activation is detected in purely cortical lesions. [see comment]. J. Neuropathol. Exp. Neurol. 64 (2005) 147-155
17. Colom L.V. Septal networks: relevance to theta rhythm, epilepsy and Alzheimer's disease. J. Neurochem. 96 (2006) 609-623
18. de Lanerolle N.C., and Lee T.S. New facets of the neuropathology and molecular profile of human temporal lobe epilepsy. Epilepsy Behav. 7 (2005) 190-203
19. De Simoni M.G., Storini C., Barba M., Catapano L., Arabia A.M., Rossi E., and Bergamaschini L. Neuroprotection by complement (C1) inhibitor in mouse transient brain ischemia. J. Cereb. Blood Flow Metab. 23 (2003) 232-239
20. Eikelenboom P., and Veerhuis R. The role of complement and activated microglia in the pathogenesis of Alzheimer's disease. Neurobiol. Aging 17 (1996) 673-680
21. Engel J.J. Outcome with respect to epileptic seizures. In: Engel J.J. (Ed). Surgical Treatment of the Epilepsies (1993), Raven Press, New York 609-621
22. Fan R., and Tenner A.J. Complement C1q expression induced by Abeta in rat hippocampal organotypic slice cultures. Exp. Neurol. 185 (2004) 241-253
23. Ferrier C.H., Aronica E., Leijten F.S., Spliet W.G., van Huffelen A.C., van Rijen P.C., and Binnie C.D. Electrocorticographic discharge patterns in glioneuronal tumors and focal cortical dysplasia. Epilepsia 47 (2006) 1477-1486
24. Fonseca M.I., Kawas C.H., Troncoso J.C., and Tenner A.J. Neuronal localization of C1q in preclinical Alzheimer's disease. Neurobiol. Dis. 15 (2004) 40-46
25. Fraser D.A., Bohlson S.S., Jasinskiene N., Rawal N., Palmarini G., Ruiz S., Rochford R., and Tenner A.J. C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J. Leukoc. Biol. 80 (2006) 107-116
26. Gagliardi B., Noe F., Ravizza T., Boer K., Marki N., Aronica E., and Vezzani A. Innate and adaptive immune mechanisms during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. 7th European Congress on Epileptology, Helsinki (2006) 226-227
27. Gorter J.A., Vliet van E.A., Aronica E., and Lopes da Silva F.H. Progression of spontaneous seizures after status epilepticus is related with extensive bilateral loss of hilar parvalbumin and somatostatin immunoreactive neurons. E. J. Neurosci. 13 (2001) 1-14
28. Gorter J.A., Goncalves Pereira P.M., van Vliet E.A., Aronica E., Lopes da Silva F.H., and Lucassen P.J. Neuronal cell death in a rat model for mesial temporal lobe epilepsy is induced by the initial status epilepticus and not by later repeated spontaneous seizures. Epilepsia 44 (2003) 647-658
29. Gorter J.A., van Vliet E.A., Aronica E., Breit T., Rauwerda H., Lopes da Silva F.H., and Wadman W.J. Potential new antiepileptogenic targets indicated by microarray analysis in a rat model for temporal lobe epilepsy. J. Neurosci. 26 (2006) 11083-11110
30. Griffin W.S. Inflammation and neurodegenerative diseases. Am. J. Clin. Nutr. 83 (2006) 470S-474S
31. Hansch G.M., Seitz M., and Betz M. Effect of the late complement components C5b-9 on human monocytes: release of prostanoids, oxygen radicals and of a factor inducing cell proliferation. Int. Arch. Allergy Appl. Immunol. 82 (1987) 317-320
32. Hartung H.P., Jung S., Stoll G., Zielasek J., Schmidt B., Archelos J.J., and Toyka K.V. Inflammatory mediators in demyelinating disorders of the CNS and PNS. J. Neuroimmunol. 40 (1992) 197-210
33. Hendriksen H., Datson N.A., Ghijsen W.E., van Vliet E.A., da Silva F.H., Gorter J.A., and Vreugdenhil E. Altered hippocampal gene expression prior to the onset of spontaneous seizures in the rat post-status epilepticus model. Eur. J. Neurosci. 14 (2001) 1475-1484
34. Henshall D.C., Araki T., Schindler C.K., Lan J.Q., Tiekoter K.L., Taki W., and Simon R.P. Activation of Bcl-2-associated death protein and counter-response of Akt within cell populations during seizure-induced neuronal death. J. Neurosci. 22 (2002) 8458-8465
35. Holers V.M. The complement system as a therapeutic target in autoimmunity. Clin. Immunol. 107 (2003) 140-151
36. Ichiyama T., Okada K., Lipton J.M., Matsubara T., Hayashi T., and Furukawa S. Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res. 857 (2000) 246-251
37. Jamali S., Bartolomei F., Robaglia-Schlupp A., Massacrier A., Peragut J.C., Regis J., Dufour H., Ravid R., Roll P., Pereira S., Royer B., Roeckel-Trevisiol N., Fontaine M., Guye M., Boucraut J., Chauvel P., Cau P., and Szepetowski P. Large-scale expression study of human mesial temporal lobe epilepsy: evidence for dysregulation of the neurotransmission and complement systems in the entorhinal cortex. Brain 129 (2006) 625-641
38. Leinhase, I., Schmidt, O., Thurman, J.M., Hossini, A.M., Rozanski, M., Taha, M.E., Scheffler, A., John, T., Smith, W.R., Holers, V.M., Stahel, P.F., 2006. Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. 199, 454-464.
39. Liszewski M.K., Farries T.C., Lublin D.M., Rooney I.A., and Atkinson J.P. Control of the complement system. Adv. Immunol. 61 (1996) 201-283
40. Lucas S.M., Rothwell N.J., and Gibson R.M. The role of inflammation in CNS injury and disease. Br. J. Pharmacol. 147 (2006) 232-240
41. Lukasiuk K., Kontula L., and Pitkanen A. cDNA profiling of epileptogenesis in the rat brain. Eur. J. Neurosci. 17 (2003) 271-279
42. Mathern G.W., Adelson P.D., Cahan L.D., and Leite J.P. Hippocampal neuron damage in human epilepsy: Meyer's hypothesis revisited. Prog. Brain Res. 135 (2002) 237-251
43. Mayer M.M. The complement system. Sci. Am. 229 (1973) 54-66
44. McGeer E.G., Klegeris A., and McGeer P.L. Inflammation, the complement system and the diseases of aging. Neurobiol. Aging 26 Suppl. 1 (2005) 94-97
45. Menendez M. Down syndrome, Alzheimer's disease and seizures. Brain Dev. 27 (2005) 246-252
46. Meri S., Morgan B.P., Davies A., Daniels R.H., Olavesen M.G., Waldmann H., and Lachmann P.J. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 71 (1990) 1-9
47. Moreno-Ancillo A., Cosmes Martin P.M., Dominguez-Noche C., Martin-Nunez G., Fernandez-Galan M.A., Lopez-Lopez R., Gonzalez-Hurtado J.A., and Gil-Adrados A.C. Carbamazepine induced transient monoclonal gammopathy and immunodeficiency. Allergol. Immunopathol. 32 (2004) 86-88
48. Mrak R.E., Sheng J.G., and Griffin W.S. Glial cytokines in Alzheimer's disease: review and pathogenic implications. Human Pathol. 26 (1995) 816-823
49. Osaka H., Mukherjee P., Aisen P.S., and Pasinetti G.M. Complement-derived anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. J. Cell. Biochem. 73 (1999) 303-311
50. Ozbas-Gerceker F., Gorter J.A., Redeker S., Ramkema M., van der Valk P., Baayen J.C., Ozguc M., Saygi S., Soylemezoglu F., Akalin N., Troost D., and Aronica E. Neurotrophin receptor immunoreactivity in the hippocampus of patients with mesial temporal lobe epilepsy. Neuropathol. Appl. Neurobiol. 30 (2004) 651-654
51. Pasinetti G.M., Tocco G., Sakhi S., Musleh W.D., DeSimoni M.G., Mascarucci P., Schreiber S., Baudry M., and Finch C.E. Hereditary deficiencies in complement C5 are associated with intensified neurodegenerative responses that implicate new roles for the C-system in neuronal and astrocytic functions. Neurobiol. Dis. 3 (1996) 197-204
52. Poser C.M., and Brinar V.V. Epilepsy and multiple sclerosis. Epilepsy Behav. 4 (2003) 6-12
53. Ravizza T., Boer K., Redeker S., Spliet W.G.M., van Rijen P.C., Troost D., Vezzani A., and Aronica E. Expression and cellular distribution of interleukin-1 beta and the interleukin-1 receptor type 1 in focal cortical dysplasia and glioneuronal tumors. Epilepsia 46 274 (2005) (3.003)
54. Ravizza T., Boer K., Redeker S., Spliet W.G., van Rijen P.C., Troost D., Vezzani A., and Aronica E. The IL-1beta system in epilepsy-associated malformations of cortical development. Neurobiol. Dis. 24 (2006) 128-143
55. Romijn H.J., van Uum J.F., Breedijk I., Emmering J., Radu I., and Pool C.W. Double immunolabeling of neuropeptides in the human hypothalamus as analyzed by confocal laser scanning fluorescence microscopy. J. Histochem. Cytochem. 47 (1999) 229-236
56. Rus H., Cudrici C., and Niculescu F. C5b-9 complement complex in autoimmune demyelination and multiple sclerosis: dual role in neuroinflammation and neuroprotection. Ann. Med. 37 (2005) 97-104
57. Shen Y., Li R., McGeer E.G., and McGeer P.L. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 769 (1997) 391-395
58. Singhrao S.K., Neal J.W., Morgan B.P., and Gasque P. Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp. Neurol. 159 (1999) 362-376
59. Thom M., D'Arrigo C., and Scaravilli F. Hippocampal sclerosis with hypertrophy of end folium pyramidal cells. Acta Neuropathol. 98 (1999) 107-110
60. Thomas R.J. Seizures and epilepsy in the elderly. Arch. Intern. Med. 157 (1997) 605-617
61. Uysal H., Cevik I.U., Soylemezoglu F., Elibol B., Ozdemir Y.G., Evrenkaya T., Saygi S., and Dalkara T. Is the cell death in mesial temporal sclerosis apoptotic?. Epilepsia 44 (2003) 778-784
62. van Vliet E.A., Aronica E., Redeker S., and Gorter J.A. Expression and cellular distribution of major vault protein: a putative marker for pharmacoresistance in a rat model for temporal lobe epilepsy. Epilepsia 45 (2004) 1506-1516
63. van Vliet E.A., da Costa Araujo S., Redeker S., van Schaik R., Aronica E., and Gorter J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 130 (2007) 521-534
64. Veerhuis R., Janssen I., De Groot C.J., Van Muiswinkel F.L., Hack C.E., and Eikelenboom P. Cytokines associated with amyloid plaques in Alzheimer's disease brain stimulate human glial and neuronal cell cultures to secrete early complement proteins, but not C1-inhibitor. Exp. Neurol. 160 (1999) 289-299
65. Vezzani A., and Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 46 (2005) 1724-1743
66. Wanschitz J., Maier H., Lassmann H., Budka H., and Berger T. Distinct time pattern of complement activation and cytotoxic T cell response in Guillain-Barre syndrome. Brain 126 (2003) 2034-2042
67. Whitney K.D., and McNamara J.O. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. J. Neurosci. 20 (2000) 7307-7316
68. Wieser H.G., and Epilepsy I.C.O.N.O. ILAE Commission Report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 45 (2004) 695-714
69. Wyler A.R., Dohan C., Schweitzer J.B., and Berry III A.D. A grading system for mesial temporal pathology (hippocampal sclerosis) fram anterior temporal lobectomy. J. Epilepsy 5 (1992) 220-225
70. Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., and Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10837-10842
71. Xiong Z.Q., Qian W., Suzuki K., and McNamara J.O. Formation of complement membrane attack complex in mammalian cerebral cortex evokes seizures and neurodegeneration. J. Neurosci. 23 (2003) 955-960
72. Zanjani H., Finch C.E., Kemper C., Atkinson J., McKeel D., Morris J.C., and Price J.L. Complement activation in very early Alzheimer disease. Alzheimer Dis. Assoc. Disord. 19 (2005) 55-66